Nasdaq Approves Listing of Canary’s Staked Injective ETF

Nasdaq has approved the listing of Canary Capital’s staked Injective ETF, which will trade under the ticker INJC and stake at least 90% of its INJ holdings while charging a 1.10% annual sponsor fee. The approval marks another step in the expansion of crypto exchange-traded products beyond bitcoin and ether, bringing a staking-enabled altcoin fund to a major U.S. exchange. Injective’s INJ token stands to gain broader access to traditional brokerage accounts through the listing, though the filing did not disclose initial assets or seed funding. The 90% staking commitment means the fund intends to pass through network rewards rather than simply hold the token, a structure that could appeal to yield-seeking investors. What to watch next is the fund’s actual launch date, its initial assets under management, and whether staking rewards are distributed to shareholders or reinvested.